阿柏西普（阿瓦斯汀）与糖尿病性黄斑水肿。在出现明显视力丧失的情况下的首选血管内皮生长因子抑制剂。
Aflibercept (Eylea) and diabetic macular oedema. A first-choice VEGF inhibitor in case of marked visual loss.
出版信息
Prescrire Int. 2015 Sep;24(163):207.
PMID:26417628
Abstract
Overall, VEGF inhibitors administered by intravitreal injection have a similar harm-benefit balance. However, a publicly funded trial has shown that aflibercept is more effective than ranibizumab and bevacizumab in patients with marked loss of visual acuity.
摘要
总体而言，通过玻璃体腔内注射给予的血管内皮生长因子（VEGF）抑制剂具有相似的利弊平衡。然而，一项公共资助的试验表明，在视力显著丧失的患者中，阿柏西普比雷珠单抗和贝伐单抗更有效。
Zotero 插件